Chicago Equity Partners LLC Buys 580 Shares of USANA Health Sciences (USNA)

Chicago Equity Partners LLC increased its stake in USANA Health Sciences (NYSE:USNA) by 4.7% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 12,885 shares of the company’s stock after purchasing an additional 580 shares during the quarter. Chicago Equity Partners LLC owned approximately 0.05% of USANA Health Sciences worth $1,107,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in USNA. SG Americas Securities LLC bought a new position in USANA Health Sciences in the 1st quarter worth $137,000. US Bancorp DE raised its holdings in USANA Health Sciences by 730.1% in the 4th quarter. US Bancorp DE now owns 2,374 shares of the company’s stock worth $176,000 after purchasing an additional 2,088 shares during the period. Creative Planning bought a new position in USANA Health Sciences in the 4th quarter worth $219,000. State Board of Administration of Florida Retirement System bought a new position in USANA Health Sciences in the 1st quarter worth $236,000. Finally, Stone Ridge Asset Management LLC bought a new position in USANA Health Sciences in the 4th quarter worth $265,000. 50.69% of the stock is currently owned by institutional investors.

A number of equities analysts recently commented on the company. TheStreet cut USANA Health Sciences from a “b+” rating to a “c+” rating in a report on Tuesday, February 6th. Pivotal Research raised their target price on USANA Health Sciences from $80.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, February 7th. ValuEngine raised USANA Health Sciences from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd. Finally, Sidoti cut USANA Health Sciences from a “buy” rating to a “neutral” rating in a report on Wednesday, January 24th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $95.00.

Shares of USNA stock opened at $118.25 on Friday. USANA Health Sciences has a 52-week low of $52.80 and a 52-week high of $119.00. The firm has a market capitalization of $2.76 billion, a price-to-earnings ratio of 29.13 and a beta of 0.76.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings results on Tuesday, April 24th. The company reported $1.19 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.14. USANA Health Sciences had a return on equity of 27.92% and a net margin of 6.47%. The business had revenue of $292.00 million during the quarter, compared to analyst estimates of $268.93 million. During the same quarter in the prior year, the business posted $0.91 EPS. USANA Health Sciences’s revenue for the quarter was up 14.4% compared to the same quarter last year. equities analysts expect that USANA Health Sciences will post 4.4 earnings per share for the current fiscal year.

In other USANA Health Sciences news, insider David Mulham Mulham sold 14,733 shares of the stock in a transaction on Wednesday, May 16th. The stock was sold at an average price of $113.03, for a total value of $1,665,270.99. Following the completion of the sale, the insider now owns 14,733 shares in the company, valued at approximately $1,665,270.99. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO G Doug Iiekking sold 510 shares of the stock in a transaction on Wednesday, May 2nd. The stock was sold at an average price of $105.54, for a total value of $53,825.40. The disclosure for this sale can be found here. Insiders sold a total of 604,362 shares of company stock valued at $50,493,263 in the last quarter. 53.20% of the stock is currently owned by company insiders.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

Institutional Ownership by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply